MX2020001399A - Agentes antifungicos con actividad mejorada en ph acido. - Google Patents
Agentes antifungicos con actividad mejorada en ph acido.Info
- Publication number
- MX2020001399A MX2020001399A MX2020001399A MX2020001399A MX2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A MX 2020001399 A MX2020001399 A MX 2020001399A
- Authority
- MX
- Mexico
- Prior art keywords
- fungal
- conditions
- under
- enfumafungin
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Los compuestos antifúngicos triterpenoides derivados de enfumafungina se utilizan para tratar o prevenir infecciones fúngicas que ocurren en o bajo condiciones ácidas en donde el pH es inferior a aproximadamente 7, debido a su inesperada eficacia mejorada bajo tales condiciones. Los triterpenoides derivados de enfumafungina (o sales o hidratos farmacéuticamente aceptables de los mismos) son inhibidores de la síntesis de (1,3)-ß-D-glucano y son útiles en el tratamiento o prevención de infecciones por hongos o levaduras que ocurren en áreas anatómicas que tienen un pH bajo, tal como la cavidad vaginal, o bajo condiciones ambientales ácidas locales tales como las observadas en abscesos fúngicos, empiema o infecciones del tracto gastrointestinal superior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541370P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/044619 WO2019028034A1 (en) | 2017-08-04 | 2018-07-31 | Antifungal agents with enhanced activity in acidic ph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001399A true MX2020001399A (es) | 2020-08-06 |
Family
ID=63209698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001399A MX2020001399A (es) | 2017-08-04 | 2018-07-31 | Agentes antifungicos con actividad mejorada en ph acido. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11534433B2 (es) |
| EP (2) | EP4169514B1 (es) |
| JP (1) | JP7214714B2 (es) |
| KR (1) | KR102807716B1 (es) |
| CN (2) | CN111093655A (es) |
| AU (2) | AU2018309718B2 (es) |
| BR (1) | BR112020002290A2 (es) |
| CA (1) | CA3071940A1 (es) |
| DK (1) | DK3661503T3 (es) |
| EA (1) | EA202090445A1 (es) |
| ES (1) | ES2932658T3 (es) |
| FI (1) | FI3661503T3 (es) |
| HR (1) | HRP20221414T1 (es) |
| HU (1) | HUE060508T2 (es) |
| LT (1) | LT3661503T (es) |
| MA (1) | MA49751B1 (es) |
| MD (1) | MD3661503T2 (es) |
| MX (1) | MX2020001399A (es) |
| PL (1) | PL3661503T3 (es) |
| PT (1) | PT3661503T (es) |
| RS (1) | RS63746B1 (es) |
| SI (1) | SI3661503T1 (es) |
| SM (1) | SMT202200461T1 (es) |
| TW (1) | TWI805600B (es) |
| WO (1) | WO2019028034A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230149376A1 (en) * | 2019-02-27 | 2023-05-18 | Scynexis, Inc. | Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia |
| CA3140637A1 (en) * | 2019-05-16 | 2020-11-19 | Scynexis, Inc. | Antifungal agents, like ibrexafungerp for candida auris decolonization |
| WO2022140646A1 (en) * | 2020-12-26 | 2022-06-30 | Mycovia Pharmaceuticals, Inc | Dosing regimen for oteseconazole |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| US7863465B2 (en) | 2006-04-03 | 2011-01-04 | Merck Sharp & Dohme Corp. | Antifungal agents |
| EA018337B1 (ru) * | 2008-08-12 | 2013-07-30 | Мерк Шарп Энд Дом Корп. | Противогрибковые средства |
| CA2731941C (en) | 2008-08-12 | 2016-09-27 | Merck Sharp & Dohme Corp. | Derivatives of enfumafungin as inhibitors of(1,3)-beta.-d-glucan synthase |
| EP3247711B1 (en) | 2015-01-19 | 2022-03-09 | Scynexis, Inc. | Novel salts and polymorphs of scy-078 |
| US11110102B2 (en) * | 2017-04-10 | 2021-09-07 | Scynexis, Inc. | Antifungal agents used in combination |
-
2018
- 2018-07-31 SM SM20220461T patent/SMT202200461T1/it unknown
- 2018-07-31 EP EP22193944.0A patent/EP4169514B1/en active Active
- 2018-07-31 ES ES18755632T patent/ES2932658T3/es active Active
- 2018-07-31 MX MX2020001399A patent/MX2020001399A/es unknown
- 2018-07-31 EA EA202090445A patent/EA202090445A1/ru unknown
- 2018-07-31 CN CN201880059398.2A patent/CN111093655A/zh active Pending
- 2018-07-31 US US16/636,230 patent/US11534433B2/en active Active
- 2018-07-31 WO PCT/US2018/044619 patent/WO2019028034A1/en not_active Ceased
- 2018-07-31 CN CN202410653474.XA patent/CN118542868A/zh active Pending
- 2018-07-31 AU AU2018309718A patent/AU2018309718B2/en active Active
- 2018-07-31 DK DK18755632.9T patent/DK3661503T3/da active
- 2018-07-31 LT LTEPPCT/US2018/044619T patent/LT3661503T/lt unknown
- 2018-07-31 SI SI201830810T patent/SI3661503T1/sl unknown
- 2018-07-31 PL PL18755632.9T patent/PL3661503T3/pl unknown
- 2018-07-31 RS RS20221058A patent/RS63746B1/sr unknown
- 2018-07-31 HR HRP20221414TT patent/HRP20221414T1/hr unknown
- 2018-07-31 CA CA3071940A patent/CA3071940A1/en active Pending
- 2018-07-31 MD MDE20200607T patent/MD3661503T2/ro unknown
- 2018-07-31 FI FIEP18755632.9T patent/FI3661503T3/fi active
- 2018-07-31 HU HUE18755632A patent/HUE060508T2/hu unknown
- 2018-07-31 KR KR1020207005972A patent/KR102807716B1/ko active Active
- 2018-07-31 MA MA49751A patent/MA49751B1/fr unknown
- 2018-07-31 BR BR112020002290-0A patent/BR112020002290A2/pt unknown
- 2018-07-31 EP EP18755632.9A patent/EP3661503B1/en not_active Revoked
- 2018-07-31 PT PT187556329T patent/PT3661503T/pt unknown
- 2018-07-31 JP JP2020505869A patent/JP7214714B2/ja active Active
- 2018-08-03 TW TW107127013A patent/TWI805600B/zh active
-
2022
- 2022-11-18 US US17/990,656 patent/US20230364067A1/en not_active Abandoned
-
2024
- 2024-10-21 AU AU2024227501A patent/AU2024227501A1/en active Pending
- 2024-12-03 US US18/967,641 patent/US20260000656A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| MX2019014980A (es) | 3-fenilisoxazolin-5-carboxamidas de acidos y esteres tetrahidro y dihidrofuranocarboxilicos con efecto herbicida. | |
| PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
| MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| CL2022001439A1 (es) | Combinación de antagonista del receptor lpa1 de azetidina con pirfenidona y, o nintedanib. | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| EA201691808A8 (ru) | Кортикостероидные композиции для местного применения | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2015014351A (es) | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir transporte de fosfato. | |
| PH12019502062A1 (en) | Skin barrier composition | |
| MX2020001399A (es) | Agentes antifungicos con actividad mejorada en ph acido. | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| MX382601B (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
| CL2015002817A1 (es) | Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| JOP20190156B1 (ar) | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 | |
| CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
| PH12015501739A1 (en) | Topical antifungal composition for treating onychomycosis | |
| PH12015501210A1 (en) | Use of pidotimod to treat psoriasis | |
| PE20190321A1 (es) | Composiciones farmaceuticas | |
| MX386903B (es) | Composiciones farmacéuticas tópicas y uso en el tratamiento de afecciones cutáneas. |